Cited 7 times in
Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박형천 | - |
dc.contributor.author | 최훈영 | - |
dc.date.accessioned | 2017-10-26T07:11:03Z | - |
dc.date.available | 2017-10-26T07:11:03Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/151704 | - |
dc.description.abstract | BACKGROUND/AIMS: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in patients with favorable prognostic features. In this study, we aimed to investigate the antiproteinuric effect and tolerability of low-dose valsartan (an angiotensin II receptor blocker) therapy in normotensive IgAN patients with minimal proteinuria of less than 0.5 to 1.0 g/day. METHODS: Normotensive IgAN patients, who had persistent proteinuria with a spot urine protein-to-creatinine ratio of 0.3 to 1.0 mg/mg creatinine, were recruited from five hospitals and randomly assigned to either 40 mg of valsartan as the low-dose group or 80 mg of valsartan as the regular-dose group. Clinical and laboratory data were collected at baseline, and at 4, 8, 12, and 24 weeks after valsartan therapy. RESULTS: Forty-three patients (low-dose group, n = 23; regular-dose group, n = 20) were enrolled in the study. Proteinuria decreased significantly not only in the regular-dose group but also in the low-dose group. The change in urine protein-to-creatinine ratio at week 24 was -41.3% ± 26.1% (p < 0.001) in the regular-dose group and -21.1% ± 45.1% (p = 0.005) in the low-dose group. In the low-dose group, blood pressure was constant throughout the study period, and there was no symptomatic hypotension. In the regular-dose group, blood pressure decreased at weeks 8 and 12. No significant change in glomerular filtration rate, serum creatinine level, or serum potassium level was observed during the study period. CONCLUSIONS: Our results suggest that low-dose valsartan can significantly reduce proteinuria without causing any intolerability in normotensive IgAN patients with minimal proteinuria. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Korean Association of Internal Medicine | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Angiotensin II Type 1 Receptor Blockers/administration & dosage* | - |
dc.subject.MESH | Angiotensin II Type 1 Receptor Blockers/adverse effects | - |
dc.subject.MESH | Biomarkers/urine | - |
dc.subject.MESH | Blood Pressure | - |
dc.subject.MESH | Creatinine/urine | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glomerulonephritis, IGA/diagnosis | - |
dc.subject.MESH | Glomerulonephritis, IGA/drug therapy* | - |
dc.subject.MESH | Glomerulonephritis, IGA/physiopathology | - |
dc.subject.MESH | Glomerulonephritis, IGA/urine | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Proteinuria/diagnosis | - |
dc.subject.MESH | Proteinuria/drug therapy* | - |
dc.subject.MESH | Proteinuria/physiopathology | - |
dc.subject.MESH | Proteinuria/urine | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Valsartan/administration & dosage* | - |
dc.subject.MESH | Valsartan/adverse effects | - |
dc.title | Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial | - |
dc.type | Article | - |
dc.publisher.location | Korea (South) | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Young-Il Jo | - |
dc.contributor.googleauthor | Ha-Young Na | - |
dc.contributor.googleauthor | Ju-Young Moon | - |
dc.contributor.googleauthor | Sang-Woong Han | - |
dc.contributor.googleauthor | Dong-Ho Yang | - |
dc.contributor.googleauthor | Sang-Ho Lee | - |
dc.contributor.googleauthor | Hyeong-Cheon Park | - |
dc.contributor.googleauthor | Hoon-Young Choi | - |
dc.contributor.googleauthor | So-Dug Lim | - |
dc.contributor.googleauthor | Jeong-Hae Kie | - |
dc.contributor.googleauthor | Yong-Kyu Lee | - |
dc.contributor.googleauthor | Sug-Kyun Shin | - |
dc.identifier.doi | 10.3904/kjim.2014.266 | - |
dc.contributor.localId | A04226 | - |
dc.contributor.localId | A01759 | - |
dc.relation.journalcode | J02883 | - |
dc.identifier.eissn | 2005-6648 | - |
dc.identifier.pmid | 26874511 | - |
dc.subject.keyword | Angiotensin receptor antagonists | - |
dc.subject.keyword | Glomerulonephritis, IGA | - |
dc.subject.keyword | Proteinuria | - |
dc.subject.keyword | Safety | - |
dc.subject.keyword | Treatment outcome | - |
dc.contributor.alternativeName | Park, Hyeong Cheon | - |
dc.contributor.alternativeName | Choi, Hoon Young | - |
dc.contributor.affiliatedAuthor | Choi, Hoon Young | - |
dc.contributor.affiliatedAuthor | Park, Hyeong Cheon | - |
dc.citation.volume | 31 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 335 | - |
dc.citation.endPage | 343 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, Vol.31(2) : 335-343, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 45718 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.